Basecamp Research

Basecamp Research appointed Richard Pearce, former Biogen executive, as Chief Business Officer. Andy Conrad, S32 GP and former Verily CEO, joins the board.

Leadership read: A deliberate hiring build-out is a statement of intent about Basecamp Research's next phase in Biotech & Pharma. It points to deepening executive bench strength over the coming quarters, clustered around the capabilities being bet on. Across EMEA, the seniority and function of the hires map where the company thinks it is headed.

curated · 2026-09-24 · context →

Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.

Leadership read: Basecamp Research has moved its proprietary biodiversity-derived protein models from a research asset into a commercial workflow layer. By embedding EDEN inside Claude Science, the company has effectively transferred part of its scientific discovery surface area to Anthropic's interface, which means the value Basecamp captures now depends on adoption velocity within Claude's user base rather than direct customer relationships it controls. That is a meaningful structural shift: the company has traded distribution control for reach, and the quality of the integration, how tightly EDEN's outputs map to what working scientists actually need at the antibiotic design and vaccine-target prioritization stages, will determine whether this becomes a durable revenue channel or a visibility play. This is one of twelve partnership signals we have tracked in the last 90 days, though the Basecamp-Anthropic integration stands largely alone among them in combining frontier AI infrastructure with wet-lab biological intelligence. The closest adjacent move in the set is the Relation-GSK expanded collaboration, which similarly deepens a scientific partnership rather than initiating one. The broader pattern of AI-native platforms absorbing domain-specific scientific models via API or integration agreements is accelerating; what makes this instance structurally different is the specificity of the domain, antimicrobial resistance and vaccine prioritization, which carries embedded regulatory and clinical-translation complexity. Companies operating at the seam of AI infrastructure and applied life sciences face rising demand for leadership in scientific product management, commercial partnerships, and regulatory-pathway fluency. The market is moving toward operators who can translate model outputs into workflows that are defensible to procurement committees inside pharma and public-health institutions, a functional gap that pure AI platform experience and pure scientific experience, taken separately, do not close.

curated · 2026-06-30 · context →